Compare ODC & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ODC | NVCR |
|---|---|---|
| Founded | 1941 | 2000 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Miscellaneous manufacturing industries | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.5B |
| IPO Year | 1994 | 2015 |
| Metric | ODC | NVCR |
|---|---|---|
| Price | $70.99 | $13.26 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $25.71 |
| AVG Volume (30 Days) | 119.6K | ★ 1.7M |
| Earning Date | 12-07-2026 | 10-29-2026 |
| Dividend Yield | ★ 1.31% | N/A |
| EPS Growth | ★ 50.45 | 21.79 |
| EPS | ★ 1.69 | N/A |
| Revenue | $493,844,000.00 | ★ $655,353,000.00 |
| Revenue This Year | N/A | $12.91 |
| Revenue Next Year | N/A | $9.23 |
| P/E Ratio | $41.98 | ★ N/A |
| Revenue Growth | 1.70 | ★ 8.28 |
| 52 Week Low | $45.61 | $9.82 |
| 52 Week High | $107.00 | $21.45 |
| Indicator | ODC | NVCR |
|---|---|---|
| Relative Strength Index (RSI) | 34.84 | 40.06 |
| Support Level | $69.95 | $11.73 |
| Resistance Level | $77.92 | $18.43 |
| Average True Range (ATR) | 3.07 | 0.81 |
| MACD | -0.14 | -0.03 |
| Stochastic Oscillator | 28.10 | 33.69 |
Oil-Dri Corp of America develops, manufactures, and markets sorbent products made predominantly from clay. Its absorbent offerings, which draw liquid up, include cat litter, floor products, toxin control substances for livestock, and agricultural chemical carriers. The company has two segments based on the different characteristics of two primary customer groups, namely the Retail and Wholesale Products Group, which derives maximum revenue, and the Business-to-Business Products Group. The company's products are sold under various brands such as Cat's Pride, Jonny Cat, Amlan, Agsorb, Verge, Pure-Flo, and Ultra-Clear.
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.